$30,518.75 consulting Payment -- Gilead Sciences to Dr. Christine Edwards

Hepatology Specialist Receives Over $30,000 for Rinvoq Consulting Services

This page provides a detailed analysis of a $30,518.75 consulting payment from Gilead Sciences to Dr. Christine Edwards. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$30,518.75
Payment Typeconsulting
Payment NatureConsulting Fee
Pharmaceutical CompanyGilead Sciences
PhysicianDr. Christine Edwards
NPI Number1896239397
Physician SpecialtyHepatology
LocationCity, IN
Date of Payment2024-04-27
Related Drug/DeviceRinvoq
Conflict AssessmentHigh -- Significant

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Gilead Sciences made a $30.5K consulting payment to Christine Edwards, a Hepatology specialist in City, IN. The payment was associated with Rinvoq. The payment of $30,518.75 to Dr. Christine Edwards for consulting services related to Rinvoq is a significant amount. This payment falls under 'Consulting Fee' and was made by Gilead Sciences, a major pharmaceutical company. The payment was made on April 27, 2024, indicating a recent engagement.

Patient Guidance: What This Payment Means for You

Patients should be aware that their healthcare providers may receive payments from pharmaceutical companies for consulting services related to specific medications. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

A $30,518.75 consulting fee for a Hepatology specialist is on the higher end compared to typical consulting arrangements, though specific project scopes can vary widely.

Regulatory Context: Sunshine Act Requirements

This payment is subject to reporting requirements under the Physician Payments Sunshine Act, requiring disclosure of the nature of the payment and the involved parties.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $30.5K payment for?

This was a consulting payment of $30.5K from Gilead Sciences to Christine Edwards, categorized as "Consulting Fee". It was associated with Rinvoq. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Christine Edwards accept pharmaceutical money?

Yes, Christine Edwards received this $30.5K payment from Gilead Sciences. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Christine Edwards's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $30.5K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Hepatology?

To compare this payment against Hepatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Hepatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Christine Edwards's relationship with Gilead Sciences?

The payment amount is substantial for a single consulting engagement. This $30.5K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Hepatology?

The payment is specifically tied to the drug Rinvoq, suggesting a focus on its development or promotion.

What should patients do after learning about this payment?

Patients should be aware that their healthcare providers may receive payments from pharmaceutical companies for consulting services related to specific medications.

What else should I know about this consulting payment?

Dr. Edwards' specialty is Hepatology, which aligns with the potential use of Rinvoq.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.